The aim of this study was to describe overall survival (OS) with current first-line treatment for patients presenting with stage IV NSCLC without known EGFR or ALK tumor aberrations across a broad range of community oncology practices in the United States (US). This evidence concerns the gene EGFR and non-small cell lung carcinoma.